ASCO 2013:二线治疗之Tivantinib的3期临床试验

2013-06-06 ASCO dxy

Tivantinib是HGF的受体MET的抑制剂。这是一个3期临床试验,目标患者是在前期的全身治疗(包括索拉非尼)过程中进展或无法耐受的者,且肿瘤组织免疫组化染色证实MET高表达者。计划募集303名患者,按照2:1的比例随机接受tivantinib或安慰剂治疗。预期2015年中期可以完成研究。 Metiv-HCC: A phase III clinical trial evaluating ti

Tivantinib是HGF的受体MET的抑制剂。这是一个3期临床试验,目标患者是在前期的全身治疗(包括索拉非尼)过程中进展或无法耐受的者,且肿瘤组织免疫组化染色证实MET高表达者。计划募集303名患者,按照2:1的比例随机接受tivantinib或安慰剂治疗。预期2015年中期可以完成研究。

Metiv-HCC: A phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as second-line in patients (pts) with MET-high inoperable hepatocellular carcinoma (HCC).
Abstract:
Background: Tivantinibis a selective, non-ATP competitive, oral inhibitor of MET,the tyrosine kinase receptor for hepatocyte growth factor (HGF). METover-expression is associated with poor prognosis in HCC patients. Aphase Ib study (Santoro et al, Br J Cancer, 2013) with tivantinib 360mgBID revealed no worsening of liver function in cirrhotic HCC pts. Arandomized, placebo-controlled phase 2 study identified HCC patientswith high tumor MET expression at immunohistochemistry (IHC) as thetarget population for tivantinib in second line (overall survival: 7.2months on tivantinib, 3.8 months on placebo, HR: 0.38, p=0.01), andselected 240mg BID as the appropriate dose for HCC patients (Santoro etal, Lancet Oncol, 2013).
Methods: Enrollment forthis phase III clinical trial (ARQ 197-A-U303, NCT01755767) has begun.Eligible pts must present with Child Pugh A; ECOG performance score <1; inoperable RECIST 1.1 measurable disease; adequate bone marrow, liver and kidney functions; no prior liver transplant. Pts must have progressed after or not tolerated one prior line of systemic therapy including sorafenib and their tumor samples must be deemed MET-High by IHC at a central laboratory to be eligible. Approximately 303 pts are randomized 2:1 to receive tivantinib 240mg PO twice daily or placebo. Pts are stratified by vascular invasion, metastases, and alphafetoprotein level, and they are evaluated by CT or MRI scan at 8-week intervals. The primary endpoint is overall survival (OS). Secondary endpoints include progression-free survival and safety. Treatment continues until confirmed disease progression or unacceptable toxicity. Pts discontinued from study treatment will be followed for survival. Participating centers are located in Europe, Australia, New Zealand, and the Americas. This trial is expected to complete enrollment by mid-2015, and an interim analysis is planned when approximately 60% of OS events are reached.
Clinical trial information: NCT01755767.

作者:ASCO



版权声明:
本网站所有注明“来源:梅斯医学”或“来源:MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明“来源:梅斯医学”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题

相关资讯

JCO:ASCO新指南肯定癌症患者保存卵母细胞

  根据美国临床肿瘤学会(ASCO)发布的新版新诊断癌症患者保存生育力指南,保存卵母细胞已不再只是一种经验性选择,而是成为了一种标准措施。   不过除了肯定保存卵母细胞的做法之外,新版指南提出的建议与2006年版指南几乎完全一致。新版指南还纳入了新的文献,以便为医患之间关于保存生育力问题的讨论搭建框架。这部指南发表在《临床肿瘤杂志》5月28日在线版上Fertility Preservation

ASCO 2013:醋用新方,成功检测子宫颈癌

研究人员对 15 万名印度妇女所做的调查发现,一种用醋和目测的简易检查方式能够使子宫颈癌的死亡率减少 31%。 印度研究人员周日(6月2日)在美国临床肿瘤协会在芝加哥召开的会议上表示,如果这种新型检查方式广泛实施,那么每年可以在印度减少 22,000 个宫颈癌死亡病例,每年在发展中国家减少 72,000 个死亡病例。 醋检法非常简单易用,子宫颈如果有癌前病变,涂抹醋一分钟后,癌前病变组织将呈白

ASCO 2013:培美曲塞二线治疗EGFR野生型NSCLC优于吉非替尼

背景: 培美曲塞或吉非替尼为东亚地区晚期非鳞NSCLC患者二线治疗的常规治疗手段。CTONG 0806研究为一项多中心、随机对照、开放标签的II期临床试验,该试验针对无EGFR突变的晚期NSCLC患者,旨在对培美曲塞与吉非替尼用于二线治疗时的疗效进行对比考察。 方法:本研究招募对象为局部晚期或转移性非鳞NSCLC患者,患者此前曾接受过铂制剂为基础的化疗,且第18-21外显子不存在EGFR突变。患